By Everything-PR Editorial Team · Published July 7, 2026
Topline finding
STAT and Endpoints have consolidated biotech and healthcare citation share in a way that exceeds any other vertical except Punchbowl in public affairs. BioPharma Dive holds the FDA-decisions franchise. Drugs.com and RTTNews own the structured FDA approval database lane. Fierce Pharma, Modern Healthcare, MedPage Today, and Healthcare Dive hold their respective trade-vertical lanes. NEJM surfaces as the peer-reviewed clinical authority — the healthcare equivalent of what law firm blogs do in crypto. The structural finding: healthcare is the second vertical (after crypto) where structured-authority sources (peer-reviewed journals, FDA databases) out-cite editorial on technical questions.
"STAT and Endpoints became the medical record for the AI era. Doctors and bots both cite them. Brands have to live there. The earnings call is now training data. The FDA approval database is now training data. The peer-reviewed NEJM paper is now training data. Healthcare communications used to be a three-month story — the press release, the launch, the follow-up. Now it is a ten-year story. Every word your CMO says, every label change, every adverse event report becomes how the engines describe your drug for the next decade."
| # |
Publication |
Surfaces |
Signature Franchise |
Editorial Weight |
| 1 | STAT News | 6 of 10 queries | The Readout, Biotech Scorecard, FDA coverage | High |
| 2 | Endpoints News | 4 of 10 queries | Endpoints Studio events, JPM coverage | High |
| 3 | BioPharma Dive | 2 of 10 queries | FDA Decisions to Watch franchise | High |
| 4 | Drugs.com | 2 of 10 queries | Structured FDA approval database | High |
| 5 | RTTNews | 2 of 10 queries | FDA Calendar franchise | Medium |
| 6 | Fierce Pharma / Fierce Biotech | 1 of 10 queries | Industry trade authority | High (trade) |
| 7 | Modern Healthcare | 1 of 10 queries | Hospital and insurance trade | High (trade) |
| 8 | MedPage Today | 1 of 10 queries | Clinical news for physicians | High (trade) |
| 9 | New England Journal of Medicine (NEJM) | 1 of 10 queries | Peer-reviewed clinical authority | High (peer-reviewed) |
| 10 | Healthcare Dive | 1 of 10 queries | Healthcare industry trade | Medium (trade) |
The Top 10 — Profiles
1. STAT News
The dominant biotech and healthcare publication in our capture. STAT surfaced on FDA flashpoints, biotech IPO outlook, biotech scorecard, FDA topic page, AdCom coverage, and pharma trade reporting. Named senior writers (Adam Feuerstein, Meghana Keshavan, Matthew Herper, Ed Silverman, John Wilkerson, Allison DeAngelis, Elaine Chen) create deep attribution. Multiple newsletter franchises (The Readout, The Readout LOUD, D.C. Diagnosis) and structured trackers (CRISPR Tracker, Breakthrough Device Tracker, Generative AI Tracker, Obesity Drug Tracker) compound the citation signal. The engines treat STAT as the authoritative biotech-and-healthcare voice.
Founded in 2015 out of Boston as a dedicated life-sciences and health newsroom, STAT built exactly the architecture generative engines reward: a named, credentialed masthead paired with recurring, structured franchises that publish on a predictable calendar. When a model has to attribute a claim about an FDA flashpoint or a therapeutic-area readout, STAT gives it a byline, a beat, and a persistent URL to point to — the three signals retrieval systems weight most. Six of ten is not a plurality; it is dominance. For any communications team working biotech or pharma, the practical read is that STAT is no longer one placement among many but the default node the engines route through, and displacing it requires either the same beat writer or a structured source the model trusts more.
Sample query: FDA approval decisions biotech 2026
What it surfaced: FDA flashpoints to watch in 2026, biotech IPO outlook, biotech scorecard franchise (Adam Feuerstein), FDA topic page with named-writer attribution, trade-press authority on FDA decisions.
2. Endpoints News
The institutional biotech publication. Endpoints surfaced on JPM event coverage, FDA outlook events, health tech analysis, and industry awards franchises (E100, Endpoints Women in Biopharma, LGBTQ+ leaders). Endpoints Studio events franchise creates a structured editorial calendar the engines pull from year-round. Strong on the institutional-investor and senior-executive audience signal.
Launched in 2016, Endpoints reads to the engines as the industry's internal wire — the outlet biopharma executives and investors read to know what their own sector is doing. Its awards franchises function as citation infrastructure: the E100, the Women in Biopharma list, and the LGBTQ+ leaders recognitions are structured, annual, name-dense documents that models return to whenever a query touches leadership, momentum, or who-to-watch. Where STAT wins the FDA-decision and clinical-flashpoint questions, Endpoints owns the deal, conference, and executive-movement questions. The two are complementary rather than substitutable, which is why a healthcare communications program that has cracked one still has real citation surface to gain by cracking the other.
Sample query: Biotech industry analysis 2026
What it surfaced: Named source on JPM Healthcare Conference coverage, FDA outlook event analysis, Endpoints E100 franchise, broader biopharma industry editorial.
3. BioPharma Dive
Industry-Dive's biopharma vertical. Strong on FDA decisions to watch franchise (quarterly, with named writers like Ben Fidler) and structured industry analysis. The Industry Dive network signal (Healthcare Dive, BioPharma Dive, Pharma Manufacturing Dive) creates cross-vertical citation surface area.
BioPharma Dive's advantage is format discipline. The quarterly "FDA decisions to watch" franchise packages an inherently messy set of regulatory catalysts into a consistent, scannable, named-author structure — the kind of predictable scaffold a model can extract cleanly and cite with confidence. Because it sits inside the broader Industry Dive network, a single query can pull authority that compounds across sibling verticals, and the shared editorial template means the engines encounter the same trusted shape whether the question is drug development, hospital systems, or manufacturing. Two of ten understates its strategic position: on the specific question of upcoming FDA catalysts, it is a first-call source.
Sample query: FDA decisions to watch second quarter
What it surfaced: 5 FDA decisions to watch in the second quarter of 2026 franchise. Named writer attribution (Ben Fidler) and structured FDA-events analysis. Strong on Replimune, Novo Nordisk, Eli Lilly, Ionis competitive analysis.
4. Drugs.com
The structured drug approval database. Drugs.com surfaced as the named reference on novel drug approvals 2026 with full approval-history attribution per drug. Structured-data signal (approval date, company, treatment indication, summary) is exactly the format LLMs are trained to elevate. The medical-pharmacist authorship attribution (Melisa Puckey, BPharm) adds credentialed-author signal.
Drugs.com is the clearest illustration in this capture of a pattern that recurs across regulated verticals: a reference database can out-cite editorial not because it reports better but because it is shaped better for extraction. Each approval entry is effectively a pre-structured record — drug name, approval date, sponsor, indication, mechanism — mapped almost one-to-one onto the fields an engine wants to return. Layer credentialed pharmacist review on top and the model gets both structure and authority in a single source. For pharma communications, the takeaway is concrete: getting a newly approved product accurately and completely represented in this kind of structured database is now an answer-engine placement, not a back-office housekeeping task.
Sample query: New FDA drug approvals 2026
What it surfaced: Structured FDA approval database with named pharmacist authorship and per-drug approval history. The engines route specific-drug questions to Drugs.com.
5. RTTNews
Mid-tier financial news with strong FDA Calendar franchise. RTTNews Biotech Investor surfaced on FDA decisions facing biotech stocks queries with structured calendar format (PDUFA dates, AdCom dates, CRL outcomes). The structured-data plus investor-tier audience signal compounds.
RTTNews earns its citation weight the same way Drugs.com does — through structure rather than brand. Its FDA Calendar renders regulatory catalysts as a dated, sortable ledger of PDUFA and advisory-committee milestones, which is precisely the shape a model wants when a buyer asks what decisions are coming and when. The editorial weight here is Medium, and that is the useful signal: an outlet without premium brand recognition still surfaces on catalyst questions purely because it publishes the answer in the format the engines prefer. It confirms that in FDA-decision queries, retrievability of structure can beat reputation.
Sample query: Biotech stocks FDA decisions June 2026
What it surfaced: FDA Calendar / Biotech Investor franchise with structured PDUFA-date tracking, CRL outcome reporting, large-cap to small-cap biotech coverage.
6. Fierce Pharma / Fierce Biotech
Long-running industry trade publication. Fierce Pharma covers pharmaceutical industry news with deep beat reporting. Fierce Biotech covers biotech specifically. Trade-specialist signal compounds on industry-practitioner questions where mainstream financial press is too narrow and STAT or Endpoints is too premium.
The Fierce network occupies the practitioner middle of the market — the commercial, manufacturing, and pricing beats that matter enormously to people inside the industry but rarely break into mainstream financial headlines. That specificity is the whole point: on a narrow trade question, the engines route to the outlet that has covered that beat for years rather than to a generalist. One of ten in a capture skewed toward FDA-decision and investor queries likely undersells Fierce's true footprint on commercial-side pharma questions, and a broader query set is exactly the kind of thing the Phase 0 refresh will test.
Sample query: Pharma industry news trade
What it surfaced: Long-running trade authority on pharmaceutical industry news, drug pricing, manufacturing, and commercial-side biopharma coverage.
7. Modern Healthcare
The hospital and insurance trade publication. Modern Healthcare's coverage of hospital operations, health insurance, and provider business is the citation source for the systems-side of healthcare. Different audience from STAT (biotech investors) — Modern Healthcare's readers are hospital and health-plan executives.
Modern Healthcare marks a real boundary line in the vertical. Where the top of this list is biotech-and-pharma, Modern Healthcare owns the provider-and-payer economy — hospital finance, health-system consolidation, insurance dynamics, the business of delivering care. The engines treat it as the authority for a genuinely different buyer than the one asking about drug approvals, which is why it surfaces on systems questions that STAT and Endpoints do not compete for. For communications teams on the delivery side of healthcare rather than the therapeutics side, this is the node to work, and its single surface here reflects a query set weighted toward FDA and biotech rather than any weakness in its lane.
Sample query: Hospital business trends
What it surfaced: Named trade authority on hospital and insurance industry coverage — distinct from biotech-investor focused publications by audience and editorial focus.
8. MedPage Today
Clinical news for practicing physicians. MedPage Today surfaced on clinical-medicine queries where the audience is doctors and other clinicians. Strong on conference coverage, peer-reviewed study summaries, and clinical-trial reporting. The clinician-audience signal compounds on clinical-practice questions.
MedPage Today sits between trade press and the peer-reviewed literature: it translates primary clinical evidence into practice-facing reporting written for the physicians who will act on it. That translation role is valuable to an engine because it bridges the gap between a dense journal paper and a plain-language answer, often with a named clinical reviewer attached. On clinical-practice questions — how a readout changes management, what a guideline update means at the bedside — MedPage is the kind of source the model can cite without either oversimplifying or over-technicalizing. Its footprint should expand on any query set weighted toward clinical medicine rather than FDA logistics.
Sample query: Clinical medicine news physicians
What it surfaced: Named source on clinical news for physicians, peer-reviewed study summaries, and structured medical conference coverage.
9. New England Journal of Medicine (NEJM)
The peer-reviewed clinical authority. NEJM surfaced on clinical-evidence questions as the primary source of peer-reviewed clinical research. Structured peer-review process plus the Massachusetts Medical Society institutional signal creates the highest credibility marker in healthcare citation. Different from trade press — NEJM is the underlying-research authority that trade publications cite.
NEJM is the deepest layer in the healthcare citation stack. Published by the Massachusetts Medical Society and dating to the early nineteenth century, it is the source that other sources cite — the primary evidence the trade press summarizes and the databases index. To a retrieval engine, a peer-reviewed NEJM paper carries a credibility signal nothing in the editorial tier can match: methodology, review, and institutional imprimatur all attached to a permanent, precisely-worded record. That it appears only once here is a function of a query set built around FDA decisions and market questions rather than clinical evidence. The strategic implication is the sharpest in this report — for a drug, the pivotal trial published in NEJM becomes the model's canonical description of that drug's efficacy for years, which makes peer-reviewed publication itself a communications decision.
Sample query: Clinical trial peer reviewed evidence
What it surfaced: Named peer-reviewed authority on clinical-evidence questions. The engines elevate NEJM citations on the highest-credibility clinical questions.
10. Healthcare Dive
Industry Dive's healthcare vertical. Different from BioPharma Dive in audience focus (Healthcare Dive covers the broader healthcare-systems and policy side; BioPharma Dive covers drug development). The Dive editorial format (named writers, structured weekly digests, daily news) compounds citation weight across the broader healthcare landscape.
Healthcare Dive is the systems-and-policy counterpart to its BioPharma sibling, and the pairing shows how the Industry Dive template scales across a vertical: the same named-writer, structured-digest format that earns citations on drug development also earns them on provider economics, payer policy, and regulatory shifts. The engines encounter a familiar, trusted shape and route accordingly. Its single surface here reflects the biotech-weighted query set rather than any ceiling on its authority, and on a broader healthcare-systems question it competes directly with Modern Healthcare for the delivery-side lane.
Sample query: Healthcare industry policy news
What it surfaced: Broader healthcare-systems and policy trade reference. Distinct from biotech-focused trade press in editorial focus and audience.
What This Means for Communicators
Three things from this capture — and each one changes where healthcare communications budget should sit.
STAT and Endpoints have consolidated biotech/healthcare citation share.
Across virtually every biotech and FDA-decision query, STAT or Endpoints surfaced first or near-first. The engines have learned that these two are the inside-the-industry authority on biotech and biopharma. For healthcare communications teams pitching biotech and pharma clients, the question is no longer whether to be in STAT or Endpoints — it is which named writer's beat covers your therapeutic area, your sector, or your FDA decision. That reframes the pitch: instead of a broad media list, the target is a specific byline whose past coverage the engines already associate with your category, because a citation from a writer the model already trusts on your beat compounds far faster than a one-off hit in a bigger outlet.
Structured FDA databases now compete with editorial for citation share.
Drugs.com, RTTNews FDA Calendar, BioPharma Dive's FDA Decisions franchise — all surfaced as primary citations on FDA-decision questions. The pattern matches crypto: in regulated categories, structured data sources with named authors and explicit attribution out-cite editorial opinion. Healthcare communications strategy now requires structured-data placement (FDA approval database listings, calendar entries, regulatory tracker placements) alongside earned media. This is work most PR teams have never owned, and it is unglamorous — verifying that an approval record is accurate, complete, and correctly attributed is not a press hit — but on the exact questions buyers ask about your product, the structured record is what the engine reads back. Accuracy in the database is now a reputational asset, and an error in it is a reputational liability that propagates into every AI answer.
Peer-reviewed medical journals are the healthcare equivalent of law firm blogs in crypto.
NEJM, JAMA, Nature Medicine, The Lancet — the peer-reviewed clinical journals surface as primary citation sources on the highest-credibility healthcare questions. They are not press, they are not trade — they are structured-authority signals the engines elevate on clinical-evidence questions. For pharmaceutical communications, peer-reviewed publication strategy is now answer-engine strategy. The clinical study published in NEJM becomes how the engines describe your drug for the next decade. That collapses a wall the industry has long kept up between medical-affairs publication planning and corporate communications: the journal in which a pivotal trial lands, the clarity of its abstract, and the framing of its conclusions are no longer purely scientific decisions but decisions about how a machine will summarize the product to every future buyer who asks.
Notable Absences
Several publications widely treated as healthcare authorities did not surface heavily in this 10-query capture: BioSpace, FiercePharma's deeper coverage, JAMA, Nature Medicine, The Lancet, Pharma Manufacturing Dive, Pharmaceutical Executive, Becker's Hospital Review. The capture skewed toward FDA-decision and biotech-investor queries that favor STAT, Endpoints, and structured drug approval databases. The Phase 0 trend refresh on clinical-evidence queries will determine whether the peer-reviewed journals (JAMA, Nature Medicine, The Lancet) surface more heavily, and on healthcare-systems queries whether Becker's Hospital Review and Modern Healthcare expand their citation share.
Methodology
Engines tested: Google Search and Google AI Overviews. Future editions will expand to ChatGPT, Claude, Perplexity, Gemini, and Google AI Overviews.
Query set: 10 buyer-intent prompts spanning FDA decisions (approval calendar, PDUFA dates, AdCom outcomes), biotech industry (IPO outlook, JPM Healthcare Conference, biotech scorecard), pharma news (drug pricing, manufacturing, deals), healthcare systems (hospital operations, insurance, policy), and clinical evidence (peer-reviewed research, clinical trial readouts).
Window: spot capture, July 7, 2026.
Definition: outlet with (a) a dedicated biotech, pharma, healthcare, or medical-research vertical, AND (b) named editors, writers, or researchers on masthead with explicit attribution. Peer-reviewed medical journals included where they surface as primary citations on clinical-evidence questions.
Exclusions: individual pharmaceutical company websites, FDA.gov primary source, Wikipedia, YouTube, pure aggregators, supplement/wellness brand marketing pages.
Surfaces: queries in which the publication appeared as a cited editorial source or named primary attribution.
How to read the counts: a "surfaces" figure is a count of buyer-intent queries in which the publication appeared as a cited source, not a share-of-voice or traffic estimate. Because the set is ten queries on a single engine pair in a single cycle, small differences between adjacent ranks should be read as directional rather than definitive; the ordering is most meaningful at the extremes and softest in the middle of the table.
Why single-engine, why now: the first-edition captures are deliberately small and fast to establish a baseline shape per vertical before the multi-engine refresh. The value of a spot capture is not statistical precision but structural signal — which types of sources the engines reach for, and in which lanes structured authority beats editorial.
Caveat: single-engine, 10-query, single-cycle pilot.
Independence: EPR does not solicit, accept, or process payment to influence rankings.
Closing — Eight Verticals, Five Cross-Vertical Patterns
This Healthcare edition closes our first-edition Publication Citation Rankings franchise — eight verticals captured over eight days. Beauty, Sports, Wellness, Crypto, Investor Relations, Public Affairs, Luxury Hospitality, and Healthcare. Each was a single-engine, single-cycle spot capture. The Phase 0 trend refresh will expand to five engines across 60-80 queries over rolling 30-day windows. Five cross-vertical patterns emerge clearly from the first-edition captures.
1. Awards franchises are the citation moat in every vertical we tested.
Allure Best of Beauty since 1996. Marie Claire US Beauty Awards. Sunset Wellness and Beauty Awards. The goop List. Condé Nast Gold List since 1995. Travel + Leisure World's Best Awards. Forbes Travel Guide Five-Star. Sports Illustrated MLB Trade Candidate Rankings. The Athletic's beat-reporting franchise. NIRI Rising Leaders Under 40. STAT Wunderkinds. Endpoints E100. Punchbowl Power List. The pattern is universal: publications with annual structured-evaluation franchises surface more often than publications without them. Awards become the citation asset.
2. Trade specialists outpunch generalists on narrow questions.
On3 owns NIL. Boardroom owns sports business. PYMNTS owns stablecoins. NIRI IR Update owns the IR profession. Bloomberg Government owns lobbying disclosure. STAT and Endpoints own biotech. Compare Retreats owns luxury wellness travel. The engines route narrow questions to specialists. The marginal return on broad mainstream press coverage decreases on profession-specific or category-specific questions. Trade-press placement now matters more than mainstream coverage for narrow citation share.
3. Named writers and editors compound citation weight.
Bloomberg writers (Dina Bass, Ruhell Amin, Jeran Wittenstein). STAT writers (Adam Feuerstein, Meghana Keshavan, Matthew Herper, Ed Silverman). The Athletic beats. Marie Claire's Hannah Baxter. Refinery29's Jacqueline Kilikita. MindBodyGreen's Hannah Frye, Alexandra Engler, Emma Loewe. Punchbowl's Jake Sherman, Anna Palmer, John Bresnahan. Across every vertical, publications with named editors and writers surface more often than publications without them. Editorial anonymity is a citation liability.
4. In regulated categories, structured-authority signals out-cite editorial.
Crypto: law firm blogs (Latham, K&L Gates, Ropes & Gray, Sidley) surfaced as primary citations on SEC and CFTC regulatory questions. Healthcare: peer-reviewed journals (NEJM) plus structured drug approval databases (Drugs.com, RTTNews FDA Calendar) surfaced as primary citations on FDA-decision questions. Investor Relations: structured financial data (Bloomberg Intelligence, FactSet) plus earnings call transcripts (Seeking Alpha, Investing.com) surfaced as primary citations. The pattern: where the question is regulated or technical, structured-authority signals with named authors and explicit attribution out-cite editorial opinion. Communications strategy in regulated categories now requires structured-data placement alongside earned media.
5. The publications PR memory tells you matter often do not match what the engines cite.
Beauty: Cosmopolitan, Glamour, InStyle, The Cut absent. Sports: USA Today Sports, NY Post Sports, Front Office Sports absent. Wellness: Well+Good, Self, Shape, Women's Health, Outside absent. Investor Relations: Financial Times, MarketWatch, CNBC absent. Public Affairs: NYT Washington Bureau, NBC/ABC/CBS/Fox politics absent. Luxury Hospitality: Wallpaper, Monocle, Tatler absent. Healthcare: BioSpace, JAMA, Nature Medicine absent in this capture. Some of these absences are sample-size artifacts the Phase 0 refresh will correct. Others reflect real structural shifts in citation share that legacy PR media lists have not yet caught up to. For communications teams, this is the most actionable finding: the publications you have been pitching for fifteen years may not be the publications the engines now cite. Audit the gap.
The Phase 0 trend refresh begins in 90 days. Five engines. Sixty to eighty queries per vertical. Rolling 30-day windows. Three to five capture cycles per refresh. The first-edition rankings will move. The cross-vertical patterns are likely to harden.
- The Citation Share Index — the brand-level research franchise. Where Publication Citation Rankings measure publisher-side citation weight, the Citation Share Index measures brand-side citation weight across category queries.
- The National Retrieval Stack™ — the nation-level analog. Measures how countries win, lose, and compound authority across AI engines.
- Publisher Survival Stack™ — the publisher operating-model framework. Scores individual publishers across Content, Distribution, Licensing, Commerce, and AI Retrieval layers.
- AI Communications Master Hub — the discipline that operationalizes what all four measurement layers surface.
- Generative Engine Optimization (GEO) — the underlying methodology publishers and brands apply to improve citation share.
- The Architects: Ronn Torossian — the founder who coined AI Communications.
